Xanthohumol Impairs the PMA-Driven Invasive Behaviour of Lung Cancer Cell Line A549 and Exerts Anti-EMT Action.
A549 Cells
Adenocarcinoma of Lung
/ pathology
Antineoplastic Agents
/ pharmacology
Cell Movement
/ drug effects
Epithelial-Mesenchymal Transition
/ drug effects
Flavonoids
/ pharmacology
Humans
Lung Neoplasms
/ pathology
Neoplasm Invasiveness
/ pathology
Propiophenones
/ pharmacology
Signal Transduction
/ drug effects
AKT
EMT
ERK
FAK
MMPs
invasion
lung cancer
migration
xanthohumol
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
12 06 2021
12 06 2021
Historique:
received:
25
04
2021
revised:
10
06
2021
accepted:
10
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Xanthohumol (XN), the main prenylated flavonoid from hop cones, has been recently reported to exert significant proapoptotic, anti-proliferative, and growth inhibitory effects against lung cancer in both in vitro and in vivo studies. However, its anti-metastatic potential towards this malignancy is still unrevealed. Previously, we indicated that the human lung adenocarcinoma A549 cell line was sensitive to XN treatment. Therefore, using the same tumour cell model, we have studied the influence of XN on the phorbol-12-myristate-13-acetate (PMA)-induced cell migration and invasion. The effects of XN on the expression/activity of pro-invasive MMP-9 and MMP-2 and the expression of MMP inhibitors, i.e., TIMP-1 and TIMP-2 (anti-angiogenic factors), were evaluated. Additionally, the influence of XN on the production of the key pro-angiogenic cytokine, i.e., VEGF, and the release of TGF-β, which is both a pro-angiogenic cytokine and an epithelial-mesenchymal transition (EMT) stimulator, was studied. Furthermore, the influence of XN on the expression of EMT-associated proteins such as E-cadherin and α-E-catenin (epithelial markers), vimentin and N-cadherin (mesenchymal markers), and Snail-1 (transcriptional repressor of E-cadherin) was studied. To elucidate the molecular mechanism underpinning the XN-mediated inhibition of metastatic progression in PMA-activated cells, the phosphorylation levels of AKT, FAK, and ERK1/2 kinases, which are signalling molecules involved in EMT program activation, were assayed. The results showed that XN in non-cytotoxic concentrations impaired the PMA-driven migratory and invasive capacity of A549 cells by decreasing the level of expression of MMP-9 and concomitantly increasing the expression of the TIMP-1 protein, i.e., a specific blocker of pro-MMP-9 activation. Moreover, XN decreased the PMA-induced production of VEGF and TGF-β. Furthermore, the XN-treatment counteracted the PMA-induced EMT of the A549 cells by the upregulation of E-cadherin and α-E-catenin and the downregulation of N-cadherin, vimentin, and Snail-1 expression. The proposed mechanism underlying the anti-invasive XN activity involved the inhibition of the ERK/MAPK pathway and suppression of FAK and PI3/AKT signalling. Our results suggesting migrastatic properties of XN against lung cancer cells require further verification in in vivo assays.
Identifiants
pubmed: 34204745
pii: cells10061484
doi: 10.3390/cells10061484
pmc: PMC8231538
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Flavonoids
0
Propiophenones
0
xanthohumol
T4467YT1NT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cancers (Basel). 2014 Jan 27;6(1):240-96
pubmed: 24473089
Biochim Biophys Acta Gen Subj. 2019 Nov;1863(11):129408
pubmed: 31386885
Sci Rep. 2014 Dec 08;4:7355
pubmed: 25483453
Eur J Cancer. 2010 May;46(7):1177-80
pubmed: 20307970
FASEB J. 2006 Mar;20(3):527-9
pubmed: 16403733
Braz J Med Biol Res. 2000 Feb;33(2):179-89
pubmed: 10657057
Anticancer Res. 2010 Sep;30(9):3333-9
pubmed: 20944105
J Thorac Oncol. 2011 Sep;6(9):1601-12
pubmed: 21849857
Toxicology. 2016 May 16;357-358:65-73
pubmed: 27317025
Mol Cancer Ther. 2008 Sep;7(9):2692-702
pubmed: 18790751
J Cell Sci. 2003 Apr 15;116(Pt 8):1409-16
pubmed: 12640026
Front Biosci. 2003 May 01;8:d982-96
pubmed: 12700132
J Thorac Oncol. 2006 Sep;1(7):749-51
pubmed: 17409953
Front Oncol. 2017 Aug 28;7:193
pubmed: 28894699
Lung Cancer. 2015 Mar;87(3):249-57
pubmed: 25595426
Lung Cancer. 2002 May;36(2):115-24
pubmed: 11955645
Mol Cell Biochem. 2010 Feb;335(1-2):181-93
pubmed: 19768635
Front Pharmacol. 2018 May 22;9:530
pubmed: 29872398
Biochem Pharmacol. 2012 Jun 15;83(12):1634-42
pubmed: 22445931
BMC Cancer. 2018 Oct 1;18(1):939
pubmed: 30285678
Mol Med. 2012 Dec 06;18:1292-302
pubmed: 22952060
Arch Toxicol. 2013 Jul;87(7):1301-12
pubmed: 23503627
Phytomedicine. 2006 Nov;13(9-10):732-4
pubmed: 16678392
J Cell Biochem. 2008 Aug 1;104(5):1699-707
pubmed: 18348194
Nutr Res. 2011 Feb;31(2):77-87
pubmed: 21419311
Oncogene. 2002 Mar 28;21(14):2245-52
pubmed: 11948407
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
J Cell Biol. 2005 Jan 3;168(1):29-33
pubmed: 15631989
Oncogene. 2017 Jan 12;36(2):242-253
pubmed: 27270426
J Transl Med. 2012 Sep 03;10:183
pubmed: 22943793
Chest. 2013 May;143(5 Suppl):e40S-e60S
pubmed: 23649449
Exp Mol Med. 2007 Feb 28;39(1):97-105
pubmed: 17334233
Lung Cancer. 2009 Apr;64(1):13-21
pubmed: 18771813
Phytomedicine. 2009 Apr;16(4):369-76
pubmed: 19201179
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cancer. 2007 Nov 1;110(9):2007-11
pubmed: 17823911
Nat Cell Biol. 2000 Feb;2(2):76-83
pubmed: 10655586
Cell Cycle. 2014;13(15):2334-9
pubmed: 25483184
Anticancer Res. 2016 Apr;36(4):1545-51
pubmed: 27069130
PLoS One. 2015 May 26;10(5):e0127464
pubmed: 26011160
Oncol Rep. 2020 Oct;44(4):1365-1374
pubmed: 32945473
Eur J Cancer. 2005 Sep;41(13):1941-54
pubmed: 15953717
Chem Biol Interact. 2013 May 25;203(3):565-72
pubmed: 23562496
Oncotarget. 2014 Jun 15;5(11):3880-94
pubmed: 25003810
Mol Med Rep. 2015 Dec;12(6):7992-8002
pubmed: 26498639
Chem Biol Interact. 2015 Oct 5;240:110-8
pubmed: 26297991
Chem Res Toxicol. 2019 Feb 18;32(2):222-233
pubmed: 30608650
Mol Med Rep. 2017 Dec;16(6):8301-8306
pubmed: 28983601
Oncotarget. 2017 Jul 4;8(34):57058-57071
pubmed: 28915654
J Thorac Dis. 2010 Sep;2(3):154-9
pubmed: 22263037
Oncol Rep. 2001 Mar-Apr;8(2):421-4
pubmed: 11182067
Front Pharmacol. 2020 Jan 28;10:1614
pubmed: 32116665
Neuropharmacology. 2016 Nov;110(Pt A):362-375
pubmed: 27487563
BMC Cancer. 2012 Mar 28;12:121
pubmed: 22455335
Sci Rep. 2017 Oct 30;7(1):14300
pubmed: 29085026
J Clin Med. 2016 Jun 29;5(7):
pubmed: 27367735
Int J Clin Exp Med. 2014 Nov 15;7(11):4352-6
pubmed: 25550954
Oncol Rep. 2016 Sep;36(3):1199-206
pubmed: 27460444
Prostate. 2010 Jul 1;70(10):1119-26
pubmed: 20333698